ライフサイエンスコーパス: biglycan

1 an-1,2,4, glypican-1,2,3, versican, decorin, biglycan).

2 in (which is closely related in structure to biglycan).

3 l-surface sites, such as the protein core of biglycan.

4 I, apoB, apoE, and the vascular proteoglycan biglycan.

5 inked oligosaccharides) forms of decorin and biglycan.

6 in disaccharides liberated from decorin and biglycan.

7 overlaps with the expression of decorin and biglycan.

8 % identical (and 70% similar) to decorin and biglycan.

9 the isolated binding factors as decorin and biglycan.

10 rich repeat chondroitin sulfate proteoglycan biglycan.

11 upon the chondroitin sulfate side chains of biglycan.

12 elated with increased expression of secreted biglycan.

13 LPL for versican and 20 microgram/ml LPL for biglycan.

14 te-oxidized LDL bound poorly to versican and biglycan.

15 cked by the structurally homologous protein, biglycan.

16 ology with peptide antibodies to decorin and biglycan.

17 antially rescued by the addition of purified biglycan.

18 and also had reduced mRNA levels compared to biglycan.

19 ructures of the core proteins of decorin and biglycan.

20 synthesis of versican, perlecan, and decorin/biglycan.

21 assemble glycosaminoglycans onto recombinant biglycan.

22 function for the decorin-family proteoglycan biglycan.

23 in the production of approximately 10 mg of biglycan/10(9) cells per 24 h.

24 rain increased mRNA for versican (3.2-fold), biglycan (2.0-fold), and perlecan (2.0-fold), whereas de

25 ved in lipid signaling) and up-regulation of biglycan (a member of the small leucine-rich protein fam

26 GF-beta, but protein expression and mRNA for biglycan, a proteoglycan present in fibrotic tissue, was

27 Biglycan, a proteoglycan that is structurally closely re

28 Biglycan, a related proteoglycan, had no effect.

29 ican-positive regions also immunostained for biglycan, a small leucine-rich dermatan sulfate proteogl

30 Biglycan, a small leucine-rich proteoglycan, is a nonfib

31 predominantly synthesized by neurons, and of biglycan, a small, leucine-rich chondroitin sulfate prot

32 Several lines of evidence indicate that biglycan acts by recruiting utrophin protein to the musc

33 r analysis shows that, with the exception of biglycan, all known SLRP genes reside in three gene clus

34 oE-containing but not apoE-free HDL and that biglycan also binds LDL.

35 protein retention by regulating synthesis of biglycan and also by altering glycosaminoglycan synthesi

36 Thus, biglycan and decorin appear to be essential for maintain

37 Biglycan and decorin are small dermatan sulfate-containi

38 of (125)I-labeled decorin and -biglycan, and biglycan and decorin competed for the SR-A-mediated cell

39 e of newly synthesized and total accumulated biglycan and decorin decreased by approximately 25%.

40 ermine if blocking TFGbeta signaling changed biglycan and decorin distribution.

41 In conclusion, both biglycan and decorin from atherosclerotic plaque possess

42 Biglycan and decorin from plaque exhibited a 24-75% and

43 Biglycan and decorin have been overexpressed in eukaryot

44 Loss of the ability of biglycan and decorin in atherosclerotic lesions to regul

45 PG-2 and PG-3 were identified as biglycan and decorin in Western blot analyses using anti

46 to analyze the HCII-stimulatory activity of biglycan and decorin isolated from normal human aorta an

47 The temporal expression of biglycan and decorin on the apical surface of MEE, combi

48 Immunohistochemistry of both biglycan and decorin revealed expression on the apical a

49 ression of specific messenger RNA (mRNA) for biglycan and decorin was determined with quantitative re

50 The renal proteoglycans biglycan and decorin were detectable in glomeruli, with

51 bserved in the cell-associated matrix, while biglycan and decorin were secreted into the medium of mo

52 asporin gene structure is similar to that of biglycan and decorin with 8 exons.

53 For biglycan and decorin, iduronate content was linearly cor

54 ed position at the C-terminal domain of both biglycan and decorin, is found in similar microenvironme

55 actor-beta (TGF-beta)-binding proteoglycans, biglycan and decorin, prevents TGF-beta from proper sequ

56 Biglycan and decorin, proteoglycans of the extracellular

57 Interestingly, the levels of biglycan and decorin, small leucine-rich proteoglycans,

58 n this study, we identified 2 proteoglycans, biglycan and decorin, that were expressed in the palatal

59 ers of the small leucine-rich proteoglycans, biglycan and decorin, we uncovered a role for these two

60 third peak contained the small proteoglycans biglycan and decorin.

61 eficient in 2 extracellular matrix proteins, biglycan and fibromodulin (bgn(-/0)fmod(-/-)).

62 ritis that is deficient in two ECM proteins, biglycan and fibromodulin (Bgn(-/0)Fmod(-/-)).

63 Analysis of these data shows that biglycan and fibromodulin are critical for TMJ subchondr

64 condylar cartilage integrity and identified biglycan and fibromodulin as novel key players in regula

65 In vivo interactions of biglycan and fibromodulin, two SLRPs highly expressed in

66 ritical for chondrogenesis and binds to both biglycan and fibromodulin.

67 nd aggrecan ((374)ALGS) fragments as well as biglycan and link protein from the aortic wall.

68 activity reduced the LDL binding ability of biglycan and released LDL from human aortic lesions.

69 showed a significant relation between renal biglycan and renal apolipoprotein B content.

70 Renal biglycan and renal apolipoprotein B were colocalized, an

71 oE), and extracellular matrix proteoglycans (biglycan and versican) were identified on adjacent secti

72 ADAMTS-5 was accompanied by accumulation of biglycan and versican, the major lipoprotein-binding pro

73 DL, since it enables its binding to vascular biglycan and versican.

74 en fibrils in tendons from mice deficient in biglycan and/or fibromodulin are structurally and mechan

75 lly biomolecules that can induce osteogenic (biglycan) and fibrogenic (fibromodulin, decorin) phenoty

76 ns), proteoglycans (eg, versican, syndecans, biglycan), and glycosaminoglycans (eg, hyaluronan, hepar

77 analysis using specific antisera to decorin, biglycan, and aggrecan.

78 The spatial relationships of versican, biglycan, and apoE were compared on 68 human coronary ar

79 d for binding of (125)I-labeled decorin and -biglycan, and biglycan and decorin competed for the SR-A

80 unostaining results indicated that aggrecan, biglycan, and decorin are distributed throughout the thi

81 alpha, alone or in combination, on aggrecan, biglycan, and decorin core protein gene transcription an

82 The molecular sizes of versican, biglycan, and decorin increased in response to Ox-LDL, a

83 coding the cartilage proteoglycans aggrecan, biglycan, and decorin is differentially regulated by IFN

84 this recombinant protein to cleave aggrecan, biglycan, and decorin was investigated.

85 ontains three major proteoglycans; aggrecan, biglycan, and decorin.

86 GF-beta binding protein-1 (LTBP-1), decorin, biglycan, and fibromodulin can bind and potentially inhi

87 llular matrix remodeling such as hyaluronan, biglycan, and fibronectin.

88 Three genes (lumican, biglycan, and insulin-like growth factor binding protein

89 Immunolabeling for carboxymethyllysine, biglycan, and lipoprotein lipase was found in D-galactos

90 modeling genes include desmoplakin, SPARCL1, biglycan, and PECAM.

91 Strain also increased versican, biglycan, and perlecan core proteins, with a concomitant

92 ce and matrix proteoglycans (e.g., perlecan, biglycan, and syndecans 1 and 3) and mitogenesis-related

93 ng enzyme prolysyl oxidase, the proteoglycan biglycan, and the basement membrane protein laminin 5.

94 ed high levels of alpha-smooth muscle actin, biglycan, and the extra domain A (EDA or EIIIA) form of

95 gulated the expression of osteonectin/SPARC, biglycan, and type I collagen in calvaria.

96 c segments contained substantial deposits of biglycan, apoE, apoA-I, and apoB.

97 e binding of native LDL to both versican and biglycan, approaching saturation at 30-40 microgram/ml L

98 Decorin and biglycan are class I small leucine-rich proteoglycans (S

99 r these results demonstrate that decorin and biglycan are WISP-1 binding factors that can mediate and

100 es provide further evidence that decorin and biglycan assume different structures in solution.

101 d to interact in vitro with the proteoglycan biglycan (Bg), but the direct participation of apoE in t

102 Biglycan (Bgn) and Fibromodulin (Fmod) are subtypes of t

103 of an extracellular matrix, and we identify biglycan (Bgn) and fibromodulin (Fmod) as two critical c

104 The extracellular matrix protein biglycan (Bgn) is a leucine-rich proteoglycan that is in

105 Biglycan (bgn) is a small leucine-rich proteoglycan enri

106 The biglycan binding site was mapped to the COOH-terminal th

107 Biglycan binding to alpha-dystroglycan was confirmed by

108 In vitro studies demonstrated that biglycan binds apoE-containing but not apoE-free HDL and

109 Biglycan binds MuSK and the levels of this receptor tyro

110 specifically stimulated mRNA expression for biglycan (but not versican or decorin), which was correl

111 Biglycan, but not decorin, from atherosclerotic plaque c

112 dies of structural and functional domains of biglycan by transient eukaryotic expression using the va

113 te proteoglycan, epiphycan, from decorin and biglycan by using dissociative extraction of bovine feta

114 was completely rescued by reintroduction of biglycan by viral transfection.

115 of elastin synthesis and assembly, and that biglycan can act as an important modulator of the compos

116 e cells were transduced with a GAG-deficient biglycan cDNA-containing retroviral vector (LmBSN).

117 Bone matrix markers (biglycan, COL1A1, tenascin C, and fibronectin) and low-d

118 6 (MT3-MMP) and decorin, and upregulation of biglycan, collagen V, collagen XII, PAI-1, Scleraxis, an

119 corneal regions, corroborating the idea that biglycan compensates for the loss of decorin.

120 genesis assays using recombinant decorin and biglycan confirmed a functional compensation, with both

121 oncentrations in plasma and increased aortic biglycan content compared with mice that received either

122 meruli, with a significant increase in renal biglycan content in diabetic mice on the high-cholestero

123 The increased renal biglycan content in diabetic nephropathy probably contri

124 The biglycan core protein also shows a similar steep transit

125 of recombinant chondroitin sulfate-modified biglycan core protein and restoration of fibroblast grow

126 nt vaccinia virus, vBGN4 encoding the mature biglycan core protein as a polyhistidine fusion protein

127 d core protein are very similar, whereas the biglycan core protein exhibits closer similarity to the

128 levels (-79%) and transcription rate of the biglycan core protein gene (-46%).

129 The inhibition of aggrecan, decorin, and biglycan core protein gene expression by the combination

130 ycan steady-state mRNA levels (-62%) and the biglycan core protein gene transcription rate (-18%).

131 lycan mRNA or the transcription rates of the biglycan core protein gene.

132 Both recombinant biglycan proteoglycan and biglycan core protein increased Wnt-induced beta-catenin

133 F-treated and wounded cultures increase both biglycan core protein synthesis and biglycan proteolytic

134 The mRNA and protein levels of biglycan, decorin, and fibromodulin increased synchronou

135 Beyond the fourth decade, decorin and biglycan decreased in all scleral regions and were prese

136 Biglycan-deficient cells treated with exogenous Wnt3a ha

137 ed protein 1 was decreased in bone formed by biglycan-deficient cells, further suggesting reduced Wnt

138 of several Wnt target genes were blunted in biglycan-deficient cells.

139 ssessed reduced activity with HCII, but only biglycan demonstrated a correlation between activity and

140 also were detected in regions with apoE and biglycan deposition.

141 a high degree of colocalization of apoE and biglycan deposits.

142 uble-deficiency of 2 SLRPs, fibromodulin and biglycan (dKO), acquire skeletal abnormalities, but thei

143 c evidence for an interaction of decorin and biglycan during corneal development and further suggest

144 sembly, a function that can be fine-tuned by biglycan during early development.

145 Biglycan (encoded by the gene Bgn) is an ECM proteoglyca

146 the small leucine-rich proteoglycan family, biglycan, enhances canonical Wnt signaling by mediating

147 Decorin and biglycan exhibited overlapping spatial expression patter

148 the B. burgdorferi s. l. complex, adhered to biglycan expressed by human endothelial cells in a flow-

149 tin sulfate chains, whereas about 50% of the biglycan expressed by UMR106 cells was substituted with

150 Finally, biglycan expression is elevated in muscle from the dystr

151 ely high levels in all developmental stages, biglycan expression was high early, decreased during dev

152 us bFGF is primarily responsible for altered biglycan expression, synthesis, and proteolytic processi

153 Decorin and biglycan extracted from normal and diseased corneas exhi

154 ronan-binding large proteoglycans), decorin, biglycan, fibromodulin, and lumican (small proteoglycans

155 oteoglycan (SLRP) family, including decorin, biglycan, fibromodulin, and lumican.

156 s and bones, were investigated by generating biglycan/fibromodulin double-deficient mice.

157 ulation of a approximately 20-kDa N-terminal biglycan fragment in the culture media.

158 We found a compensatory up-regulation of biglycan gene expression in the decorin-deficient mice,

159 glutathione-S-transferase-fused recombinant biglycan (GST-BGN) on craniofacial bone regeneration.

160 although they are predominantly beta-sheet, biglycan has a significantly higher content of alpha-hel

161 tryptase, also degraded other alarmins, i.e. biglycan, HMGB1, and IL-33, a degradation that was effic

162 at a significant portion of the glypican and biglycan immunoreactivity colocalized with nuclear stain

163 ining was selective, insofar as glypican and biglycan immunoreactivity in the nucleus was seen predom

164 s showed an abnormal stromal localization of biglycan in pathologic corneas.

165 s, keratocan, lumican, mimecan, decorin, and biglycan in solution in vitro has been compared using re

166 el role for the extracellular matrix protein biglycan in synapse stability.

167 accumulation of decorin and particularly of biglycan in the affected corneas.

168 with hypotheses that predict involvement of biglycan in the control of cell migration.

169 e investigated the expression of decorin and biglycan in the cornea of mice deficient in either SLRP

170 lts also raise the possibility of a role for biglycan in the pathogenesis, and perhaps the treatment,

171 ighly charged molecular forms of decorin and biglycan, indicating modification of the proteins with d

172 Purified biglycan induces nNOS redistribution to the plasma membr

173 Decorin and biglycan interacted directly with WISP-1 and inhibited i

174 Immunoprecipitation analysis revealed that biglycan interacts with both the canonical Wnt ligand Wn

175 The proteoglycan biglycan is a receptor molecule for flow-resistant adhes

176 Biglycan is a small chondroitin sulfate proteoglycan fou

177 Biglycan is an ECM molecule that associates with the DAP

178 Together, these results indicate that biglycan is an extracellular ligand for MuSK that is imp

179 In muscle, biglycan is detected at both synaptic and nonsynaptic re

180 llopodia on migrating cells, indicating that biglycan is found at loci at which the formation and dis

181 We conclude that biglycan is important for the maintenance of muscle cell

182 The biological function of biglycan is poorly understood, although several studies

183 inantly in the macrophage-rich core, whereas biglycan is prominent in the smooth muscle cell matrix a

184 Biglycan is synthesized as a precursor with an NH(2)-ter

185 Instead, biglycan levels were increased, highlighting the role of

186 central nervous system regions, glypican and biglycan may be involved in the regulation of cell divis

187 These results suggest that biglycan may bind apoE and apoB in atherosclerotic intim

188 ings are consistent with the hypothesis that biglycan may contribute to the pathogenesis of atheroscl

189 We propose that biglycan may serve as a reservoir for Wnt in the pericel

190 We propose that biglycan modulates BMP-4-induced signaling to control os

191 ite, removing the propeptide and producing a biglycan molecule with an NH(2) terminus identical to th

192 on of the inhibitory effects of TNF alpha on biglycan mRNA levels (-79%) and transcription rate of th

193 used, IFN gamma did not alter the levels of biglycan mRNA or the transcription rates of the biglycan

194 Comparing biglycan mRNAs, (GU)25 replaced (CA)12.

195 tic development in fetal and early postnatal biglycan null (bgn(-/o)) muscle is indistinguishable fro

196 Here, we show that biglycan null mice exhibit a mild dystrophic phenotype a

197 1 and -2, and beta1- and beta2-syntrophin in biglycan null mice.

198 parable fibril structure in the decorin- and biglycan-null corneas compared with wild-type controls.

199 Notably, the corneas of compound decorin/biglycan-null mice showed severe disruption in fibril st

200 inhibited by dermatan sulfate, decorin, and biglycan or by treatment of the cell surface with dermat

201 Neointimae that formed from cells with biglycan or empty vector contained fewer and less aggreg

202 Control cells were transduced with either biglycan or empty vector.

203 ddition of LPL to oxidized LDL together with biglycan or versican allowed the oxidized LDL to bind th

204 reduction in collagen 3), but not periostin, biglycan, or fibronectin accumulation, was improved by a

205 Versican, biglycan, perlecan, and hyaluronan were present with var

206 o be identified and characterized along with biglycan (PG-I) and decorin (PG-II).

207 ginating from types I, II, and III collagen, biglycan, prolargin, fibromodulin, fibronectin, decorin,

208 Biglycan protein and mRNA levels peaked as the palatal s

209 Biglycan protein injected into muscle becomes stably ass

210 Both recombinant biglycan proteoglycan and biglycan core protein increase

211 moval of the chondroitin sulfate chains from biglycan proteoglycan does not induce a shift to the cor

212 larity to the decorin glycoforms than to the biglycan proteoglycan form.

213 However, biglycan proteoglycan shows a broad unfolding transition

214 Far-UV CD spectroscopy of decorin and biglycan proteoglycans indicates that, although they are

215 ase both biglycan core protein synthesis and biglycan proteolytic processing, which results in the ac

216 ity and HCII stimulatory activity (r = 0.79, biglycan; r = 0.63, decorin; p < 0.05).

217 e show that the extracellular matrix protein biglycan regulates utrophin expression in immature muscl

218 and internalization) of (125)I-decorin and -biglycan, respectively.

219 This injected biglycan restores the sarcolemmal expression of alpha-dy

220 n immature muscle and that recombinant human biglycan (rhBGN) increases utrophin expression in cultur

221 Biglycan RNA steady-state levels also selectively increa

222 Furthermore, biglycan's modulation of canonical Wnt signaling affecte

223 Biglycan-, sc1-, and SIM-Ig fusion proteins selectively

224 Approximately 70% of the recombinant biglycan secreted by HT-1080 cells was substituted with

225 The structure of the recombinant biglycan secreted by these cells was defined by analyzin

226 hese findings suggest that the GAG chains of biglycan serve as inhibitors of elastin synthesis and as

227 In contrast, TNF alpha decreased biglycan steady-state mRNA levels (-62%) and the biglyca

228 This approach resulted in the cloning of biglycan, syndecan 4, collagen type I, clusterin, matrix

229 expression of TGF-beta1 and matrix proteins (biglycan, tenascin, fibronectin, and type I collagen).

230 The decorin-null tissues contained more biglycan than control tissues, suggesting that this rela

231 ng the binding of native and oxidized LDL to biglycan than versican.

232 and activity for biosynthetic processing of biglycan, the latter with kinetics superior to those of

233 In contrast, less cleavage was observed for biglycan, the most closely related proteoglycan.

234 Exposure of decorin and biglycan to 10 M urea resulted in an increase in fluores

235 nally, immunocytochemical staining localizes biglycan to the tips and edges of lamellopodia on migrat

236 ic fibers as compared with empty vector- and biglycan-transduced cells.

237 ift assay, [(35)S]SO(4)-labeled versican and biglycan, two extracellular proteoglycans secreted by va

238 Strong immunostaining for decorin, biglycan, versican, and hyaluronan is observed in both i

239 Furthermore, SAA up-regulated biglycan via the induction of endogenous transforming gr

240 Interestingly, recombinant biglycan was able to rescue impaired Wnt signaling cause

241 when the secondary structure of recombinant biglycan was disrupted by exposure to 4 M guanidine hydr

242 half of the pathologic corneas, the level of biglycan was elevated an average of seven times above no

243 The native recombinant biglycan was shown to bind to collagen type V and the co

244 eobox, Myoblast determination protein 1, and Biglycan were examined within clonal cell populations, c

245 acellular matrix proteoglycans keratocan and biglycan were quantified using ELISAs.

246 Glycoforms of biglycan were separated by imidazole gradient elution, u

247 I receptors; as well as LTBP-1, decorin, and biglycan were up-regulated during adult wound healing.

248 roblasts (MEFs) produce only fully processed biglycan, whereas MEFs derived from embryos homozygous n

249 f the hyalectan gene family; and decorin and biglycan, which are members of a separate gene family, t

250 eoglycan that may influence elastogenesis is biglycan, which possesses two GAG chains.

251 inant PLTP markedly increased HDL binding to biglycan, which suggests that PLTP may mediate lipoprote

252 Exceptions to the localization of biglycan with apolipoproteins were found in regions that